Ibis E - Search Results

1

Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.

Karnak D, Ulubay G, Kayacan O, Beder S, Ibis E, Oflaz G. Karnak D, et al. Among authors: ibis e. Lung. 2001;179(1):57-65. doi: 10.1007/s004080000047. Lung. 2001. PMID: 11479694 Clinical Trial.

2

Neuron-specific enolase and lung cancer.

Karnak D, Beder S, Kayacan O, Ibiş E, Oflaz G. Karnak D, et al. Among authors: ibis e. Am J Clin Oncol. 2005 Dec;28(6):586-90. doi: 10.1097/01.coc.0000177915.51805.6e. Am J Clin Oncol. 2005. PMID: 16317269

3

Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.

Küçük ON, Gültekin SS, Aras G, Ibiş E. Küçük ON, et al. Among authors: ibis e. Nucl Med Commun. 2006 Mar;27(3):261-6. doi: 10.1097/00006231-200603000-00009. Nucl Med Commun. 2006. PMID: 16479246

4

Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.

Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G. Ozkan E, et al. Among authors: ibis e. Nucl Med Commun. 2011 Dec;32(12):1162-8. doi: 10.1097/MNM.0b013e32834bbe09. Nucl Med Commun. 2011. PMID: 21946617

5

Clinical importance of anti-thyroglobulin auto-antibodies in patients with differentiated thyroid carcinoma: comparison with 99mTc-MIBI scans.

Küçük ON, Aras G, Kulak HA, Ibiş E. Küçük ON, et al. Among authors: ibis e. Nucl Med Commun. 2006 Nov;27(11):873-6. doi: 10.1097/01.mnm.0000243376.49378.27. Nucl Med Commun. 2006. PMID: 17021427

6

The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.

Ozkan E, Soydal C, Araz M, Kir KM, Ibis E. Ozkan E, et al. Among authors: ibis e. Nucl Med Commun. 2012 Apr;33(4):395-402. doi: 10.1097/MNM.0b013e32834f7dbe. Nucl Med Commun. 2012. PMID: 22367859

7

The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.

Ozkan E, Soydal C, Araz M, Aras G, Ibis E. Ozkan E, et al. Among authors: ibis e. Clin Nucl Med. 2012 Aug;37(8):755-8. doi: 10.1097/RLU.0b013e31825ae77b. Clin Nucl Med. 2012. PMID: 22785502

8

Hürthle cell carcinoma: a clinicopathological study of thirteen cases.

Ozlem Küçük N, Kulak H, Tokmak E, Tar P, Ibiş E, Aras G. Ozlem Küçük N, et al. Among authors: ibis e. Nucl Med Commun. 2006 Apr;27(4):377-9. doi: 10.1097/01.mnm.0000202862.74917.0c. Nucl Med Commun. 2006. PMID: 16531925

9

Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.

Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E. Kucuk ON, et al. Among authors: ibis e. Clin Nucl Med. 2013 Jul;38(7):e283-9. doi: 10.1097/RLU.0b013e3182867f17. Clin Nucl Med. 2013. PMID: 23531737 Clinical Trial.

10

Potential genotoxic effect of 186Re-HEDP on human lymphocyte cells: in-vitro evaluation with micronucleus-FISH analysis.

Ozkal-Baydin P, Gümüş-Akay G, Varol N, Rüstemoğlu A, Köroğlu R, Yüksel S, Küçük O, Aras G, Ibiş E, Sunguroğlu A. Ozkal-Baydin P, et al. Among authors: ibis e. Nucl Med Commun. 2012 Apr;33(4):415-21. doi: 10.1097/MNM.0b013e3283505188. Nucl Med Commun. 2012. PMID: 22273639

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters